Matinas Biopharma Holdings Inc reports a Return on Equity (ROE) of -371.54%.

What is MTNB's dividend yield?

Matinas Biopharma Holdings Inc offers a dividend yield of 0.00%.

What is MTNB's Quality Score?

Our AI rates MTNB's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy MTNB?

Our AI Timing Score for MTNB is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does MTNB belong to?

Matinas Biopharma Holdings Inc is classified under the Healthcare >> Biotechnology sector on the NYSE MKT exchange

Matinas Biopharma Holdings Inc (MTNB) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-05 | FS: 2026-03-31)

MTNB AI Analysis Summary

Our AI summary for MTNB: Matinas Biopharma Holdings Inc (NYSE MKT), Healthcare >> Biotechnology sector. The stock currently trades at ROE of -371.54%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 26/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

MTNB

Matinas Biopharma Holdings Inc

US:NYSE MKT STOCK Healthcare >> Biotechnology News 67

USD 0.28

-0.02 (-5.34%) Day Change

Watchlist Portfolio Compare Chart

0.24

D/E

-371.5%

ROE

-191.2%

ROA

0.00%

Div Yield

MATINAS BIOPHARMA HOLDINGS INC
TYPE: STOCK
MARKET: NYSE MKT

Compare Watchlist Myport

USD 0.28 Price -0.02 (-5.34%) Day Change	NEWS SCORE: 67

MTNB, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...

Loading chart...

38 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
ROE is decreasing significantly
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...

Quality Factors

45%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	67
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	0.28
PBV / Sector	0.62 / 44,105.10 GREAT
Earning Per Share	-1.66

PE / Sector	N/A / 19.37
PEG or PE/Growth / Sector	N/A / 1.06
Average 1M Daily Value	4.59 M GREAT
Average 1W Daily Value	1.21 M GREAT

Timing Factors

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

43%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	N/A / 97.23
NPM Average (%) / Sector	-1,375.94 / -1,697.84
NPM Change Average (%) / Sector	N/A / 5,097.59
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-191.15 / 185,260.64
ROA Average (%) / Sector	-128.90 / 36,684.64
ROA Change Average (%) / Sector	90.29 / 422,221.42 GREAT
ROE (%) / Sector	-371.54 / 243,761.81
ROE Average (%) / Sector	-216.35 / 48,758.38
ROE Change Average (%) / Sector	79.13 / 424,967.86 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.42

Registration Details

Analyze Date	2026-08-06 08:00:22
Symbol	MTNB
Name	MATINAS BIOPHARMA HOLDINGS INC
Sector	Healthcare >> Biotechnology
Market	NYSE MKT
Listed Shares	6.41 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	1.86 / 9,702.21

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 1545 Route 206 South, Bedminster, NJ, United States, 07921

Phone: 908 484 8805

Website: https://www.matinasbiopharma.com

Sector: Healthcare >> Biotechnology

Description: Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It offers MAT2501, an orally administered formulation of amikacin. The company was incorporated in 2013 and is based in Bedminster, New Jersey.